RCTs from over two decades ago showed better graft outcomes after treatment of acute TCMR with rabbit anti-thymocyte globulin (rATG) compared to steroids alone and guidelines suggest use of rATG in steroid resistant and vascular rejections (BANFF 2021). However, outcomes and risks-benefits are unclear in the current era of potent induction and maintenance immunosuppression.
No takes yet. Share an insight, caveat, or question.
Azmat et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: